Laurus Investment Counsel Inc. Sells 1,660 Shares of National Research Co. (NASDAQ:NRC)

Laurus Investment Counsel Inc. reduced its stake in National Research Co. (NASDAQ:NRC) by 7.4% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 20,690 shares of the company’s stock after selling 1,660 shares during the period. Laurus Investment Counsel Inc. owned 0.08% of National Research worth $818,000 at the end of the most recent reporting period.

A number of other hedge funds have also added to or reduced their stakes in NRC. Price T Rowe Associates Inc. MD lifted its position in shares of National Research by 2.5% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 9,656 shares of the company’s stock worth $360,000 after purchasing an additional 231 shares during the period. Gladius Capital Management LP lifted its position in shares of National Research by 40.0% in the 3rd quarter. Gladius Capital Management LP now owns 830 shares of the company’s stock worth $37,000 after purchasing an additional 237 shares during the period. Rhumbline Advisers lifted its position in shares of National Research by 1.4% in the 2nd quarter. Rhumbline Advisers now owns 19,331 shares of the company’s stock worth $841,000 after purchasing an additional 272 shares during the period. MetLife Investment Management LLC lifted its position in shares of National Research by 4.2% in the 4th quarter. MetLife Investment Management LLC now owns 7,239 shares of the company’s stock worth $270,000 after purchasing an additional 292 shares during the period. Finally, Summit Global Investments lifted its position in shares of National Research by 3.8% in the 3rd quarter. Summit Global Investments now owns 8,452 shares of the company’s stock worth $375,000 after purchasing an additional 310 shares during the period. 47.26% of the stock is currently owned by institutional investors.

Insider Buying and Selling at National Research

In other news, major shareholder Amandla Mk Trust sold 4,600 shares of the firm’s stock in a transaction dated Thursday, January 4th. The shares were sold at an average price of $41.22, for a total value of $189,612.00. Following the transaction, the insider now directly owns 3,833,976 shares of the company’s stock, valued at $158,036,490.72. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 2.00% of the company’s stock.

Wall Street Analyst Weigh In

Separately, TheStreet cut shares of National Research from a “b-” rating to a “c+” rating in a research report on Thursday, January 11th.

National Research Trading Down 0.5 %

NASDAQ:NRC opened at $39.40 on Thursday. National Research Co. has a 52 week low of $36.21 and a 52 week high of $47.25. The firm has a 50 day moving average of $39.56 and a 200 day moving average of $41.22. The company has a quick ratio of 0.67, a current ratio of 0.67 and a debt-to-equity ratio of 0.60. The stock has a market capitalization of $939.69 million, a price-to-earnings ratio of 31.52 and a beta of 0.42.

National Research (NASDAQ:NRC) last issued its quarterly earnings results on Tuesday, February 13th. The company reported $0.36 earnings per share (EPS) for the quarter. The business had revenue of $38.00 million for the quarter. National Research had a net margin of 20.84% and a return on equity of 47.79%.

National Research Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Monday, April 15th. Shareholders of record on Friday, March 29th will be issued a dividend of $0.12 per share. This represents a $0.48 annualized dividend and a yield of 1.22%. The ex-dividend date is Wednesday, March 27th. National Research’s payout ratio is 38.40%.

About National Research

National Research Corporation provides analytics and insights that facilitate measurement and enhancement of the patient and employee experience. Its portfolio of subscription-based solutions provides actionable information and analysis to healthcare organizations across a range of mission-critical, constituent-related elements, including patient experience, service recovery, care transitions, employee engagement, reputation management, and brand loyalty.